Clinical Trials
Braintumor Website

There are 49 trials:
Facility: Children's National Medical Center
NCT Trial Name# of Centers

NCT00085735

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
184

NCT00898079

  Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
167

NCT01096368

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
150

NCT00082745

  Study of Late-Occurring Complications in Childhood Cancer Survivors
144

NCT00736749

  Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
141

NCT01217437

  Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
138

NCT00336024

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
131

NCT00653068

  Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
87

NCT01602666

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
85

NCT00716976

  Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
77

NCT01553149

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
76

NCT02017964

  Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma
65

NCT03155620

  Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
65

NCT01381718

  Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
59

NCT03213704

  Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions
50

NCT03213678

  Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations
49

NCT03233204

  Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes
41

NCT03213665

  Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations
40

NCT02875314

  HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
26

NCT00939770

  Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
26

NCT01273090

  Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
23

NCT02323880

  Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
21

NCT01878617

  A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
20

NCT02564198

  A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
19

NCT02780804

  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
19

NCT01748149

  Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
14

NCT00867178

  Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
14

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
13

NCT01158651

  Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
12

NCT01975116

  p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
11

NCT01239316

  Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
11

NCT01514201

  Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
11

NCT02960230

  H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas
11

NCT01836549

  Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
10

NCT02717455

  Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
10

NCT02359565

  Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, or Hypermutated Brain Tumors
9

NCT01503086

  Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
9

NCT03033992

  Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
9

NCT02899715

  Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma
9

NCT01964300

  Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
8

NCT02415153

  Pomalidomide in Treating Younger Patients With Recurrent, Progressive or Refractory Central Nervous System Tumors
7

NCT03220035

  Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations
6

NCT03210714

  Pediatric MATCH: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations
5

NCT02274987

  Molecular Profiling for Individualized Treatment Plan for DIPG
5

NCT01518413

  Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
4

NCT01326104

  Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
3

NCT01497860

  Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
2

NCT01106794

  Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
1

NCT03332030

  Stem Cells in NF1 Patients With Tumors of the Central Nervous System
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites